

GETINGE AB SER. B

ISIN: SE0000202624 WKN: 4385208 Asset Class: Stock

| | |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Company | 2024/04/18 09:05:42 |
|  | Price 212.80 SEK |
| | Difference  -0.37%(-0.80) |



| | |
|------------------------|------------------------------------------------------------------|
| Contact Details | |
| GETINGE AB | Tel: +46-10-335-0000 |
| -- | Fax: +46-10-335-5640 |
| Lindholmspiren 7A | Web: http://www.getinge.com |
| 417 56 Gothenburg | E-mail: info@getinge.com |

Company Profile

Getinge AB is a medical technology company specializes in providing equipment, systems, operating rooms, intensive-care units to the healthcare and the life science industries. It offers products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. The firm operates through the following segments: Acute Care Therapies, Life Science and Surgical Workflows. The Acute Care Therapies segment offers solutions for life support in acute health conditions. The Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing and laboratory applications. The Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows. The company was founded by Olander Larsson in 1904 and is headquartered in Gothenburg, Sweden.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 16,647,000,000 | | 19,105,000,000 | | 15,069,000,000 | |
| Common stock capital | | 136,000,000 | | 136,000,000 | | 136,000,000 |
| Fixed assets | 38,452,000,000 | | 34,288,000,000 | | 30,986,000,000 | |
| Equity capital of a company | | 30,403,000,000 | | 30,453,000,000 | | 25,177,000,000 |
| Cash and cash equivalents | 2,668,000,000 | | 5,676,000,000 | | 4,076,000,000 | |
| Accrued liabilities | | 3,225,000,000 | | 3,272,000,000 | | 4,251,000,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 13,185,000,000 | | 11,993,000,000 | | 10,610,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 11,511,000,000 | | 10,947,000,000 | | 10,268,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 132,000,000 | | 133,000,000 | | 125,000,000 |
| Total assets | 55,099,000,000 | 55,099,000,000 | 53,393,000,000 | 53,393,000,000 | 46,055,000,000 | 46,055,000,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|--------|--------|--------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 11,739 | 11,082 | 10,729 |
| Equity ratio | 55.61% | 57.81% | 55.59% |
| Debt-equity ratio | 79.83% | 72.97% | 79.87% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|--------|--------|--------|
| Tax Expense Rate | 27.37% | 27.53% | 28.34% |

GETINGE AB SER. B

ISIN: SE0000202624 WKN: 4385208 Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|----------------------------------------------------------------------|----------------|----------------|----------------|
| Turnover | 31,827,000,000 | 28,292,000,000 | 27,049,000,000 |
| Net income | 2,412,000,000 | 2,491,000,000 | 2,970,000,000 |
| EBIT | 321,174,500 | 315,379,000 | 378,091,500 |
| Operating income before taxes | 3,343,000,000 | 3,472,000,000 | 4,188,000,000 |
| Cash Flow | 2,957,000,000 | 3,367,000,000 | 6,560,000,000 |
| Net interest income | -370,000,000 | -174,000,000 | -183,000,000 |
| Research and development expenses | 985,000,000 | 1,013,000,000 | 804,000,000 |
| Income taxes | 915,000,000 | 956,000,000 | 1,187,000,000 |
| Result from investments in subsidiaries, associates and other | 0 | 0 | 0 |
| Revenues per employee | 234,520 | 220,832 | 218,076 |

Board of Directors

| | |
|----------------------------------|-------------------------------|
| Johan Malmquist | Chairman of Supervisory Board |
| Barbro Fridén | Member of Supervisory Board |
| Carl Reinhold Adolf Bennet | Member of Supervisory Board |
| Kristian Samuelsson | Member of Supervisory Board |
| Cecilia Margaretha Daun-Wennborg | Member of Supervisory Board |
| Dan Frohm | Member of Supervisory Board |
| Eva Christina Malin Persson | Member of Supervisory Board |
| Fredrik Brattborn | Member of Supervisory Board |
| Frida Gustafsson | Member of Supervisory Board |
| Johan Bygge | Member of Supervisory Board |
| Pontus Kallén | Member of Supervisory Board |
| Ake Larsson | Member of Supervisory Board |

Members of Management Board

| | |
|-----------------|-------------------------------|
| Mattias Perjos | Chairman of Managing Board |
| Agneta Palmer | Member of Executive Committee |
| Anna Romberg | Member of Executive Committee |
| Carsten Blecker | Member of Executive Committee |
| Elin Frostehav | Member of Executive Committee |
| Eric Honroth | Member of Executive Committee |
| Joanna Engelke | Member of Executive Committee |
| Magnus Lundbäck | Member of Executive Committee |
| Stéphane Le Roy | Member of Executive Committee |